Department of biochemistry and Molecular biology
Noel Warfel, PhD
2011-2013 - Postdoctoral Fellow, Penn State University Hershey Medical Center Cancer Institute
2011 - Ph.D., University of California, San Diego
Currently, my research focuses on understanding of the molecular mechanisms by which hypoxia promotes tumor progression and therapeutic resistance. The PIM family of Ser/Thr kinases is a key regulator tumor cell survival, and recent reports indicate that PIM expression is upregulated under hypoxic conditions. Therefore, understanding the molecular mechanisms underlying the regulation and function of PIM kinases has the potential to produce novel therapeutic strategies to inhibit tumor cell survival and therapeutic resistance associated with tumor hypoxia.
N.A. Warfel, N. Dolloff, D.T. Dicker, J. Malysz, and W. S. El-Diery. CDK1-mediated phosphorylation of Ser668 stabalizes HIF-1a to promote tumor growth. Cell Cycle 12:3689 (2013).
N.A. Warfel and W. S. El-Deiry. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 25:52 (2013).
N.A. Warfel and A.C. Newton. PH domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J Biol Chem 287:3610 (2011).
N.A. Warfel and M. Niederst, A.C. Newton. Disruption of the interface between the PH and kinase domains of Akt is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2. J Biol Chem 286:39122 (2011).
N.A. Warfel, M. Niederst, M.W. Stevens, P.M. Brennan, M.C. Frame, and A.C. Newton. Mislocalization of the E3 ligase, beta-transducin repeat-containing protein 1 (beta-TrCP1), in the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt. J Biol Chem 286:19777 (2011).